How to Get Praluent (Alirocumab) in South Carolina

What Is Praluent and Why Would a South Carolina Doctor Prescribe It?

Praluent (alirocumab) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors on hepatocytes. By blocking PCSK9, alirocumab keeps more LDL receptors on the liver surface, pulling LDL-C out of the bloodstream. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy [1].

The clinical case for the drug is anchored by the ODYSSEY OUTCOMES trial (N=18,924), published in the New England Journal of Medicine in 2018 [2]. Patients with a recent acute coronary syndrome were randomized to alirocumab 75 to 150 mg every two weeks or placebo, on top of high-intensity statin therapy. Alirocumab reduced the composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization by 15% (hazard ratio 0.85; 95% CI 0.78, 0.93; P<0.001) [2]. Patients with baseline LDL-C at or above 100 mg/dL showed the largest absolute benefit, with a number needed to treat (NNT) of 16 over 2.8 years [2].

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states that PCSK9 inhibitors are "reasonable to add" for patients with very high-risk ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin therapy, or for patients with HeFH whose LDL-C remains at or above 100 mg/dL [3]. South Carolina physicians follow these national guidelines directly, there is no state-specific formulary mandate that alters the clinical threshold.

Who Qualifies for Praluent in South Carolina?

Two FDA-approved indications apply in South Carolina, and your prescriber will document at least one of them for prior authorization.

Heterozygous familial hypercholesterolemia (HeFH). HeFH affects roughly 1 in 250 adults in the United States, meaning an estimated 20,000 South Carolinians carry a causative variant [4]. Diagnosis rests on the Dutch Lipid Clinic Network (DLCN) criteria or a positive genetic panel showing pathogenic variants in LDLR, APOB, or PCSK9 [5]. A DLCN score of 6 or above (probable FH) is typically sufficient for commercial PA approval in SC.

Established ASCVD. This category includes prior MI, prior ischemic stroke, symptomatic peripheral artery disease, or coronary revascularization. The ACC defines "very high-risk ASCVD" as two or more major ASCVD events, or one major event plus multiple high-risk conditions such as diabetes, hypertension, eGFR <60 mL/min/1.73m², or continued smoking [3]. Documenting "very high risk" strengthens the PA substantially.

Statin intolerance or inadequate response. Most SC commercial payers also require evidence that the patient either cannot tolerate at least two statins at any dose, or has been on maximally tolerated statin therapy for at least 90 days with LDL-C still above the plan's threshold (commonly 70 mg/dL for ASCVD or 100 mg/dL for HeFH) [6]. Keep dated office notes, pharmacy fill records, and any prior statin adverse event documentation.

Labs Required Before Starting Praluent in South Carolina

A standard workup ordered before the first alirocumab prescription typically includes the following.

Fasting lipid panel. This is non-negotiable. Insurers want a baseline LDL-C value (direct or Friedewald-calculated) obtained while the patient is on maximally tolerated statin therapy. The sample must be fasting (no food for 9 to 12 hours) and drawn within 90 days of PA submission. LDL-C on alirocumab can fall below 25 mg/dL in some patients; the ODYSSEY OUTCOMES data showed no safety signal at very low LDL-C levels [2].

Comprehensive metabolic panel (CMP). Liver function tests (AST, ALT) and renal function (creatinine, eGFR) are standard. Alirocumab itself carries no hepatotoxicity signal, but baseline values document that any future LFT changes predate the drug [1].

Thyroid-stimulating hormone (TSH). Hypothyroidism causes secondary hypercholesterolemia; treating the thyroid condition alone may negate the need for a PCSK9 inhibitor. Most South Carolina cardiologists order TSH at baseline [7].

Optional genetic panel. Quest Diagnostics and Labcorp both have SC draw sites offering FH gene panels (LDLR, APOB, PCSK9, LDLRAP1). A positive result can fast-track PA with certain payers and supports a definitive HeFH diagnosis independent of LDL-C thresholds [5].

All results should be compiled in a single lab packet, ideally uploaded to your prescriber's portal or sent directly to the insurer's PA review team.

How to Get a Praluent Prescription in South Carolina: Step-by-Step

Step 1. Confirm Your Diagnosis and Eligibility

Book an appointment with a cardiologist, lipidologist, or internist licensed in South Carolina. If no in-person appointment is available within a reasonable timeframe, a telehealth visit is fully permitted under South Carolina law, SC Code Ann. §40-47-37 and the SC Board of Medical Examiners' telehealth rules allow prescribing Schedule-exempt medications (alirocumab is not a controlled substance) after a synchronous audio-video encounter [8]. Bring your most recent lipid panel, statin fill history, and any relevant cardiology records.

Step 2. Order Baseline Labs

Your prescriber will order or review the fasting lipid panel, CMP, and TSH described above. Most SC LabCorp and Quest locations return results within 24 to 48 hours. If you use HealthRX telehealth, a requisition is sent to the draw site nearest your SC zip code before the visit ends.

Step 3. Select Your Dose and Injection Schedule

The FDA-approved starting dose is 75 mg subcutaneously every two weeks, administered with the prefilled pen or autoinjector [1]. The prescriber may uptitrate to 150 mg every two weeks at 4 to 8 weeks if LDL-C response is insufficient, or switch to the 300 mg monthly dose for patients who prefer a once-monthly regimen. The 75 mg and 150 mg pens are available at most specialty pharmacies that ship to SC.

Step 4. Submit Prior Authorization

The prescriber's office submits a PA to your insurer. For commercial plans operating in South Carolina, including BlueCross BlueShield of SC, Cigna, Aetna, and United Healthcare, the PA packet typically requires:

• Confirmed diagnosis (HeFH or ASCVD) with ICD-10 code (E78.01 for HeFH, I25.10 for ASCVD)
• Current LDL-C on maximally tolerated statin, with lab date
• Statin history: names, doses, duration, and reason for any discontinuation
• Prescriber attestation that the patient has been on statin therapy for at least 90 days (or documents intolerance)
• Clinical notes supporting very-high-risk classification if applicable [3]

Most SC commercial plan PA decisions arrive within 3, 14 business days. If denied, you have the right to a peer-to-peer review call between your prescriber and the plan's medical director, and then a formal internal appeal, and then an external independent review under SC Insurance Regulation 69-64 [9].

Step 5. Fill at a Specialty Pharmacy and Arrange Injection Training

Praluent is a specialty drug under most SC formularies, meaning it dispenses through a specialty pharmacy rather than a retail chain. CVS Specialty, Walgreens Specialty (formerly AllianceRx), and Accredo (now Evernorth) all ship to South Carolina addresses [10]. Cold-chain shipping typically delivers within 2, 5 business days after PA approval. The autoinjector requires refrigeration (36, 46°F) but may sit at room temperature for up to 30 days [1]. A specialty pharmacy nurse or your prescriber's clinical staff will walk you through injection technique on the first fill.

Telehealth Prescribing for Praluent in South Carolina

South Carolina permits telehealth prescribing of non-controlled medications after a real-time audio-video encounter that meets the standard of care. The SC Board of Medical Examiners clarified in 2021 that this standard applies equally to telehealth as to in-person visits, the prescriber must review the patient's medical history, relevant labs, and current medications before issuing a prescription [8].

Nurse practitioners and physician assistants licensed in SC can also prescribe alirocumab. South Carolina NPs practice under a collaboration agreement with a physician (SC Code Ann. §40-33-34), and PAs require a supervising physician under §40-47-935 [11]. In practice, most HealthRX telehealth visits for PCSK9 inhibitors are conducted by NPs or PAs in collaboration with a board-certified cardiologist or internist on the platform.

The telehealth workflow adds roughly one to three business days compared to an in-person visit, primarily for lab result turnaround and PA submission. Total time from first telehealth visit to first injection in SC averages 10, 18 business days when a commercial PA is required.

HealthRX Praluent Access Framework for South Carolina Patients

The following four-gate framework is used internally by the HealthRX clinical team to triage SC patients requesting alirocumab:

• Gate 1 (Indication): Confirmed HeFH (DLCN score 6+) or established ASCVD. Patients who pass go to Gate 2.
• Gate 2 (Statin trial): Documented 90-day trial of maximally tolerated statin, or documented intolerance to two statins. Patients who pass go to Gate 3.
• Gate 3 (LDL-C threshold): Current LDL-C at or above 70 mg/dL (ASCVD) or 100 mg/dL (HeFH) on current therapy, confirmed by fasting lab within 90 days. Patients who pass go to Gate 4.
• Gate 4 (Insurance/cost path): Commercial PA, manufacturer patient-assistance program, or self-pay specialty pharmacy. All SC patients who reach Gate 4 receive a cost analysis before the prescription is finalized.

Patients who do not pass Gates 1, 3 are referred back to the prescriber for additional statin optimization or diagnostic workup before alirocumab is initiated.

Prior Authorization in South Carolina: What to Expect

PA denial is the most common barrier SC patients face. A 2021 analysis of PCSK9 inhibitor PA processes found that initial denial rates ran as high as 75% across commercial plans, though 54% of appeals were ultimately successful [12]. The primary reasons for denial in SC include insufficient documentation of statin trial duration, LDL-C values above threshold not recorded while on statin therapy, and missing ICD-10 coding specificity.

The American College of Cardiology's 2022 guidance on PA for lipid-lowering therapy states: "Prior authorization criteria for PCSK9 inhibitors should be consistent with evidence-based guideline recommendations and not impose administrative barriers that delay access for appropriate patients" [3]. Having this language available during a peer-to-peer appeal can be effective.

If the initial PA is denied, your prescriber has 30 days under SC law to request a peer-to-peer review. After that, a written internal appeal must be filed within the plan's stated timeframe (typically 60 to 180 days after denial notice) [9]. An independent external review by a SC Department of Insurance-approved reviewer is available if the internal appeal fails.

Cost and Patient Assistance Programs in South Carolina

The list price of Praluent is approximately $5,850 per month before insurance. Most commercially insured SC patients pay substantially less after PA approval, with copays ranging from $0 to $150 per month depending on formulary tier.

Sanofi/Regeneron Copay Card. Eligible commercially insured patients (not Medicaid or Medicare Part D) may pay as little as $0 per month through the Praluent Copay Card program [13]. The card covers the gap between insurance payment and list price, up to a plan-specific cap.

Patient Assistance Program (PAP). Uninsured or underinsured SC residents with household income at or below 400% of the federal poverty level may qualify for free Praluent through the Sanofi Patient Assistance Program. Applications require income verification, proof of SC residency, and a signed prescriber attestation [13].

SC Medicaid. As of 2025, South Carolina Medicaid does not cover alirocumab. Patients covered only by SC Medicaid will need to access alirocumab through the PAP, a clinical trial, or self-pay at specialty pharmacy negotiated rates. Evolocumab (Repatha) should be checked as an alternative, as Medicaid formularies vary and coverage may differ.

GoodRx and Mark Cuban Cost Plus. GoodRx prices for alirocumab in SC range from $4,200 to $5,600 per month without insurance, depending on pharmacy. Cost Plus Drugs does not currently carry alirocumab as it is a biologic injection not available in oral generic form.

503A Compounding Pharmacies in South Carolina and Alirocumab

Alirocumab is a large-molecule biologic monoclonal antibody. It cannot be meaningfully compounded by a 503A compounding pharmacy in South Carolina or any other state. Monoclonal antibodies require recombinant DNA manufacturing under sterile biologics production conditions that exceed the scope of any 503A or 503B compounding facility [14]. Any advertisement for "compounded alirocumab" should be treated as a regulatory red flag. The FDA has not approved a biosimilar alirocumab as of mid-2025 [1]. Patients seeking a lower-cost PCSK9 inhibitor alternative should ask their prescriber about evolocumab (Repatha) or inclisiran (Leqvio), both of which have distinct regulatory and cost profiles.

Transferring a Praluent Prescription to South Carolina

If you are moving to South Carolina from another state with an active alirocumab prescription, the transfer process is straightforward. Specialty pharmacies with national licenses, including CVS Specialty and Accredo, can transfer your prescription to a SC-based dispensing location without a new PA in most cases, provided the original PA is still within its authorization period (typically 12 months) [10]. Contact the specialty pharmacy directly with your new SC address and insurer information. If your insurer changes upon moving to SC, a new PA under the SC plan's criteria will be required, and your prior statin trial and LDL-C documentation from your previous state remain valid supporting evidence.

Your out-of-state prescriber's prescription remains valid in South Carolina for the duration stated on the script, under SC Code Ann. §39-43-30 governing out-of-state prescription validity [15]. However, for ongoing telehealth follow-up and dose adjustments, you will need a SC-licensed prescriber.

Monitoring After Starting Praluent in South Carolina

After the first injection, a repeat fasting lipid panel is typically ordered at 4 to 8 weeks to confirm LDL-C response and guide dose titration [1]. ODYSSEY OUTCOMES showed a mean LDL-C reduction of 54.7% from baseline at 48 months in the alirocumab group [2]. Patients with HeFH who begin at 75 mg every two weeks and do not reach LDL-C <70 mg/dL by week 8 are uptitrated to 150 mg every two weeks.

Ongoing monitoring includes a lipid panel every 3 to 6 months for the first year, then annually if stable [3]. Liver function testing is not required on a fixed schedule by the FDA label, but many SC cardiologists repeat a CMP annually as part of routine metabolic monitoring [7]. Injection site reactions occur in approximately 7% of alirocumab-treated patients and are typically mild and self-limiting [1].

The ODYSSEY OUTCOMES trial followed patients for a median of 2.8 years and found no significant excess of neurocognitive adverse events, new-onset diabetes, or ophthalmologic findings in the alirocumab arm compared with placebo [2]. Earlier concerns about very low LDL-C and neurocognitive function, raised by initial FOURIER trial subgroup analyses for evolocumab, have not been confirmed in dedicated prospective studies, including the EBBINGHAUS trial [16].